Taigen Biopharmaceuticals Holdings Ltd (4157) — Free Cash Flow Generation Index

Latest as of March 2025: 0.99x

Taigen Biopharmaceuticals Holdings Ltd (4157) has a Free Cash Flow Generation Index of 0.99x as of March 2025. Free cash flow of NT$66.28 Million represents 1% of operating cash flow (NT$67.16 Million). See 4157 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

FCF Generation Index

0.99x

Free Cash Flow / Operating CF

Free Cash Flow

NT$66.28 Million

TWD

Operating Cash Flow

NT$67.16 Million

TWD

Capital Expenditures

NT$874.00K

TWD

Taigen Biopharmaceuticals Holdings Ltd Free Cash Flow Generation Index (2021–2023)

Historical FCF Generation Index trend for Taigen Biopharmaceuticals Holdings Ltd across 2 annual periods. Explore cash flow to debt ratio of Taigen Biopharmaceuticals Holdings Ltd to assess how comfortably operating cash covers total debt obligations.

Annual Free Cash Flow Generation for Taigen Biopharmaceuticals Holdings Ltd (2021–2023)

Year-by-year Free Cash Flow Generation Index for Taigen Biopharmaceuticals Holdings Ltd. For the full company profile including market capitalisation, see Taigen Biopharmaceuticals Holdings Ltd (4157) total market value.

Year	FCG Index	Free Cash Flow (TWD)	Operating CF	Capital Expenditures	YoY Change
2023	0.64x	NT$13.35 Million	NT$20.74 Million	NT$7.39 Million	▼ -34.4%
2021	0.98x	NT$617.24 Million	NT$629.07 Million	NT$11.83 Million	—

FCG Index = Free Cash Flow / Operating Cash Flow. FCF = Operating CF + Capital Expenditures (capex stored negative).